AUTHORS
Siqi Li, MS, Meng-Ping Xi2, Lanping Xu, MD3, Yu Wang4, Xiaohui Zhang, MD5, Yuqian Sun, MD6, Meng Lv7, Xiao-Dong Mo, MD8, Yuan Kong9, Xiaosu Zhao10, Xiangyu Zhao, MD, PhD11, Xiaojun Huang, MD,PhD12, Ying-Jun Chang13
AFFILIATIONS
1 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
2 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
3 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
4 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
5 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
6 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
7 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
8 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
9 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
10 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
11 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
12 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
13 Peking University People’s Hospital and Peking University Institute of Hematology, Beijing, China
ABSTRACT
Background: The outcomes of patients with acute myeloid leukemia (AML) who have measurable residual disease (MRD) remain poor. The discovery of new therapeutic targets to effectively eliminate residual leukemia cells is needed.
Aim: This study aimed to investigate the role of exhausted T (Tex) cells in AML patients positive for MRD and explored novel targets expressed by residual leukemia cells that drive T-cell exhaustion.
Methods: We used single-cell transcriptomics combined with spectral flow cytometry (SFC) to systematically study whether bone marrow immune environments contain exhausted T cells in residual disease positive patients with AML after allogeneic and to explore the potential driver of T cell exhaustion. Ex vivo and in vivo gene knockout experiments were used for validation.
Results: SFC was used to identify dysfunctional CD8+ memory T cells in the bone marrow of MRD-positive AML patients who received allografts, which can be used as biomarkers to predict relapse. Our analysis showed that patients who were positive for MRD had a higher percentage of PD-1+TIGIT+LAG-3+CD8+ T cells than patients who were MRD-negative and healthy controls but were comparable to patients who experienced disease relapse. Patients with a high percentage of GAMA+GZMB+PRF+CD8+ Tem cells (the cutoff value was 8.5%) had a lower cumulative incidence of relapse (CIR) than those with a low percentage of GAMA+GZMB+PRF+CD8+ Tem cells (P=0.043). Similarly, patients with a high percentage of GAMA+GZMB+PRF+CD8+ TemRA cells (cutoff value was 15%) also had a low CIR (P=0.018). A single-cell transcriptomic analysis confirmed the presence of CD8+ Tex cells in the immunosuppressive bone marrow microenvironment of AML patients positive for MRD. Exhausted T cells, characterized by high expression of TIGIT, LAG3, and TOX as well as low expression of interleukin-2 and interferon gamma, was associated with a suppressive bone marrow immune environment, which contains immunosuppressive myeloid cells, such as CD1c+ dendritic cells, plasmacytoid dendritic cells, and monocytes. A cell–cell interaction analysis revealed an interaction between residual AML cells and CD8+ Tex cells via the macrophage migration inhibitory factor (MIF) signaling pathway. The potential role of the MIF signaling pathway in AML cell-mediated exhaustion of CD8+ T cells was validated by exploring the relationship between the MIF signaling pathway-related gene signatures (including MIF, CXCR4, CD44 and CXCR2) and the survival of AML patients in TCGA-LAML dataset. We found that patients with higher expression levels of MIF-related genes experienced shorter survival than those with lower expression levels of these genes (P=0.033). We performed an ex vivo study and observed that both residual leukemia cells from patients and AML cell lines can induce CD8+ T-cell exhaustion, the use of either MIF inhibitors or MIF gene knockout can reverse the ability of leukemia cells to induce CD8+ T-cell exhaustion. Using humanized models, we observed both delayed tumor growth and improved CD8? T-cell cytotoxicity in the MIF-KO cell-injected group.
Conclusion: Our results suggest that targeting MIF in residual leukemia cells to reverse T-cell exhaustion may represent a novel and potential strategy for MRD eradication.
DISCLOSURES
Siqi Li, MS: No relevant conflicts of interest to declare.